Cormedix (NASDAQ: CRMD) insider transactions
In the twelve months to 10 November 2026, executives and directors of Cormedix reported 8 open-market sales of 237,000 shares ($2.6m) and 0 open-market purchases, by 4 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 18 September 2026 | Dillione Janet | Director | Option exercise | +48,909 | — | 117,835 | Form 4 |
| 29 August 2026 | Zelnick Kaufman Beth | Chief Legal Officer | Shares withheld for tax | −8,424 | $8.30 | 260,684 | Form 4 |
| 29 August 2026 | Hurlburt Elizabeth | Chief Operating Officer | Shares withheld for tax | −8,076 | $8.30 | 270,463 | Form 4 |
| 29 August 2026 | Blum Susan | Chief Financial Officer | Shares withheld for tax | −8,424 | $8.30 | 124,315 | Form 4 |
| 4 February 2026 | Todisco Joseph | Chief Executive Officer | Grant or award | +77,156 | — | 774,749 | Form 4 |
| 4 February 2026 | Hurlburt Elizabeth | Chief Operating Officer | Grant or award | +36,006 | — | 278,539 | Form 4 |
| 4 February 2026 | Zelnick Kaufman Beth | Chief Legal Officer | Grant or award | +36,006 | — | 269,108 | Form 4 |
| 26 January 2026 | Duncan Gregory Scott | Director | Grant or award | +30,453 | — | 68,786 | Form 4 |
| 26 January 2026 | Kaplan Myron | Director | Grant or award | +30,453 | — | 231,487 | Form 4 |
| 26 January 2026 | Lefkowitz Steven W | Director | Grant or award | +30,453 | — | 125,951 | Form 4 |
| 26 January 2026 | Dunton Alan W | Director | Grant or award | +30,453 | — | 70,703 | Form 4 |
| 26 January 2026 | Dillione Janet | Director | Grant or award | +30,453 | — | 68,926 | Form 4 |
| 26 January 2026 | Stewart Robert A | Director | Grant or award | +30,453 | — | 66,453 | Form 4 |
| 23 January 2026 | Todisco Joseph | Chief Executive Officer | Grant or award | +225,900 | — | 724,899 | Form 4 |
| 23 January 2026 | Todisco Joseph | Chief Executive Officer | Shares withheld for tax | −27,306 | $7.27 | 697,593 | Form 4 |
| 23 January 2026 | Hurlburt Elizabeth | Chief Operating Officer | Grant or award | +93,010 | — | 253,311 | Form 4 |
| 23 January 2026 | Hurlburt Elizabeth | Chief Operating Officer | Shares withheld for tax | −10,778 | $7.27 | 242,533 | Form 4 |
| 23 January 2026 | Zelnick Kaufman Beth | Chief Legal Officer | Grant or award | +72,820 | — | 241,905 | Form 4 |
| 23 January 2026 | Zelnick Kaufman Beth | Chief Legal Officer | Shares withheld for tax | −8,803 | $7.27 | 233,102 | Form 4 |
| 23 January 2026 | Blum Susan | Chief Financial Officer | Grant or award | +72,820 | — | 142,506 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Cormedix page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.